Ovarian cancer
Conditions
Interventions
The single injection of HiDCV-OS1 and 3 times subsequent injection of GEN010 will be done in the 10 days.
This procedure is set as 1 cycle.
In the first 10 days, four times administration of drugs wil
Sponsors
Kimura Tadashi
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Primary registration 1)Patients providing a written informed consent to participate in this clinical study by voluntary agreement based on her will. 2)Patients proving a written informed consent to use ovarian cancer tissue obtained by operation etc. for making the fusion cell. 3)Age over 20 and less than or equal to 80 years old at the time of informed consent 4)Have a diagnosis of ovarian carcinoma as confirmed by histology 5)Clinical stage III or IV by FIGO2014 6)No medical history of chemotherapy against ovarian cancer, and plan to have chemotherapy in the near future 7)ECOG Performance Status 0 or 1 8)The marrow function, liver function and the kidney function must be kept as follows at the screening visit (1) leukocyte >=3,000/mcL (2) platelet >= 130,000/mcL (3) hemoglobin >= 8.0 g/dL. (4) AST == 3,000/mcL (2) neutrophil >= 1,500/mcL (3) platelet >= 75,000/mcL (4) hemoglobin >= 8.0 g/dL. (5) AST=< 100 IU/L (6) ALT =< 100 IU/L (7) total bilirubin =< 2.5 mg/dL (8) serum creatinine =< 2.5 mg/dL 6)ECOG Performance Status =< 2
Exclusion criteria
Exclusion criteria: Primary registration 1)Brain metastasis. 2)Serious complications such as uncontrolled active infection. 3)Medical history of other malignancy, except for the relapse-free and metastasis-free for more than 2 years after the last treatment at the registration. 4) Active autoimmune disease. 5) Receiving systemic administration of glucocorticosteroid which restrains immunity response except low dose of oral predonisone. 6) PT(%) == 58.5 sec at the screening visit. 7) Positive result of the HCV antibody, HBV, HIV, or HTLV-I test at the screening visit. 8)Inappropriate to be enrolled in this study judged by the investigators. Secondary registration 1)Withdraw the agreement after the primary registration. 2)Positive for skin prick test of GEN0101. 3)Brain metastasis. 4)Other malignancy after the primary registration. 5)Serious complications such as uncontrolled active infection. 6)Receiving systemic administration of glucocorticosteroid which restrains immunity response except low dose of oral predonisone. 7) PT(%) == 58.5 sec at the screening visit. 8)Administered with unapproved drug within 4 weeks before the secondary registration. 9)Inappropriate to be enrolled in this study judged by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety: Adverse events during the clinical trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness evaluation item. Responsibility. Induction of antitumor immunity. Tumor marker. Safety evaluation item. Adverse events due to apheresis. Blood level of anti-HVJ-E antibody and antinuclear antibody. | — |
Countries
Japan
Contacts
Public ContactKenjiro Sawada
Osaka University Hospital
Outcome results
None listed